A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

• Published in: Cancer Vol. 122; no. 22; pp. 3519 - 3528
• Main Authors: Makker, Vicky, Recio, Fernando O., Ma, Ling, Matulonis, Ursula A., Lauchle, Jennifer O., Parmar, Hema, Gilbert, Houston N., Ware, Joseph A., Zhu, Rui, Lu, Shan, Huw, Ling‐Yuh, Wang, Yulei, Koeppen, Hartmut, Spoerke, Jill M., Lackner, Mark R., Aghajanian, Carol A.
• Format: Journal Article
• Language: English
• Published: United States 15.11.2016
• Subjects: apitolisib; endometrial cancer; GDC‐0980; MAGGIE; GDC-0980; endometrial cancer; MAGGIE; apitolisib

BACKGROUND The current single‐arm, open‐label trial was designed to evaluate the activity of apitolisib (GDC‐0980), a dual phosphoinositide 3‐kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor, in patients with advanced endometrial cancer (EC). METHODS Patients with recurrent or persistent E...